Insights

Industry Leadership As the largest pharmaceutical and healthcare group in China with significant revenue, Sinopharm presents substantial opportunities for supply chain, logistics, and distribution partnerships to enhance efficiency and expand market reach.

Technological Adoption Utilizing advanced analytics tools like Baidu Analytics and Microsoft ASP.NET indicates an openness to integrating new technologies, creating potential for collaboration on digital transformation projects and data-driven solutions.

Market Trends Recent stock performance fluctuations based on moving averages suggest a dynamic market environment, highlighting opportunities to offer investment insights, financial services, or strategic consulting to optimize growth strategies.

Financial Capacity With a robust funding amount of 45 million dollars and significant revenue figures, Sinopharm is positioned to invest in product innovation, R&D, or expanding manufacturing capabilities through partnership or sponsorship opportunities.

Global Expansion Given its prominence and comprehensive subsidiaries, Sinopharm may be seeking international collaborations, including supply chain enhancements and entry into new markets, offering opportunities for solution providers in logistics, compliance, and global distribution.

Similar companies to Sinopharm

Sinopharm Tech Stack

Sinopharm uses 8 technology products and services including CNZZ, Baidu Analytics, DNN, and more. Explore Sinopharm's tech stack below.

  • CNZZ
    Analytics
  • Baidu Analytics
    Analytics
  • DNN
    Content Management System
  • Swiper
    Javascript Libraries
  • jQuery UI
    Javascript Libraries
  • Windows Server
    Operating Systems
  • Microsoft ASP.NET
    Web Frameworks
  • Microsoft IIS
    Web Servers

Media & News

Sinopharm's Email Address Formats

Sinopharm uses at least 1 format(s):
Sinopharm Email FormatsExamplePercentage
FirstLast@sinopharm.comJohnDoe@sinopharm.com
67%
LastFirst@sinopharm.comDoeJohn@sinopharm.com
24%
FirstLas@sinopharm.comJohnDoe@sinopharm.com
4%
LastFir@sinopharm.comDoeJoh@sinopharm.com
5%

Frequently Asked Questions

Where is Sinopharm's headquarters located?

Minus sign iconPlus sign icon
Sinopharm's main headquarters is located at China. The company has employees across 6 continents, including AsiaNorth AmericaEurope.

What is Sinopharm's stock symbol?

Minus sign iconPlus sign icon
Sinopharm is a publicly traded company; the company's stock symbol is SHTDY.

What is Sinopharm's official website and social media links?

Minus sign iconPlus sign icon
Sinopharm's official website is sinopharm.com and has social profiles on LinkedInCrunchbase.

What is Sinopharm's NAICS code?

Minus sign iconPlus sign icon
Sinopharm's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Sinopharm have currently?

Minus sign iconPlus sign icon
As of May 2026, Sinopharm has approximately 718 employees across 6 continents, including AsiaNorth AmericaEurope. Key team members include Vice President And Medical Doctor: V. L.Non-Executive Director And Vice Chairman: Q. C.Executive Vice President: W. L.. Explore Sinopharm's employee directory with LeadIQ.

What industry does Sinopharm belong to?

Minus sign iconPlus sign icon
Sinopharm operates in the Pharmaceutical Manufacturing industry.

What technology does Sinopharm use?

Minus sign iconPlus sign icon
Sinopharm's tech stack includes CNZZBaidu AnalyticsDNNSwiperjQuery UIWindows ServerMicrosoft ASP.NETMicrosoft IIS.

What is Sinopharm's email format?

Minus sign iconPlus sign icon
Sinopharm's email format typically follows the pattern of FirstLast@sinopharm.com. Find more Sinopharm email formats with LeadIQ.

How much funding has Sinopharm raised to date?

Minus sign iconPlus sign icon
As of May 2026, Sinopharm has raised $45M in funding. The last funding round occurred on Apr 26, 2019 for $45M.

Sinopharm

Pharmaceutical ManufacturingChina501-1000 Employees

China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group’s revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM’s revenue is estimated to be 80 billion Yuan. 
    SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA.

Section iconCompany Overview

Headquarters
China
Stock Symbol
SHTDY
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
501-1000

Section iconFunding & Financials

  • $45M

    Sinopharm has raised a total of $45M of funding over 3 rounds. Their latest funding round was raised on Apr 26, 2019 in the amount of $45M.

  • $250M$500M

    Sinopharm's revenue is estimated to be in the range of $250M$500M

Section iconFunding & Financials

  • $45M

    Sinopharm has raised a total of $45M of funding over 3 rounds. Their latest funding round was raised on Apr 26, 2019 in the amount of $45M.

  • $250M$500M

    Sinopharm's revenue is estimated to be in the range of $250M$500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.